Patent ID: 7943310

Claim:
A method for determining the likelihood that a human subject with ulcerative colitis will respond to an anti-TNFα therapy, comprising: a) preparing a sample of mRNA from a specimen obtained from a colon biopsy of a human subject with ulcerative colitis treated with the anti-TNFα therapy; b) contacting the sample with a panel of nucleic acid probes that hybridize to the nucleic acid sequences of SEQ ID NOS: 8, 9, 28, 37, and 66; c) hybridizing the sample with the panel of nucleic probes to detect levels of the mRNAs in the sample encoded by the nucleic acid sequences of SEQ ID NOS: 8, 9, 28, 37, and 66; d) comparing the levels of the mRNAs in the sample encoded by the nucleic acid sequences of SEQ ID NOS: 8, 9, 28, 37, and 66 against a reference standard of mRNAs encoded by nucleic acid sequences of SEQ ID NOS: 8, 9, 28, 37, and 66; and e) determining the likelihood that the human subject will respond to the anti-TNFα therapy based on the comparison in step d).